Why this matters
IFS notes that batch traceability from active ingredient to finished good is mandatory under cGMP. From 2026, DSCSA serialisation enforcement adds further obligations in US supply chains. A retrofitted compliance module frequently fails an EMA audit, because data integrity is interrupted at multiple points.
A real-world example
A generics manufacturer in Hesse with 540 employees replaced its grown ERP after an EMA inspection documented batch-traceability gaps. The new system was implemented under validation from day one; remediation costs would otherwise have exceeded the entire original implementation budget.
Related terms: pharma and life sciences consulting, ERP in a validated EU pharma environment, supply-chain-first pharma ERP.
What pharma ERP must cover non-negotiably
Thinking from first principles, compliance is not a feature; it is the structure of the data model. Bolt-on compliance creates two audit problems: the gap itself and the impression of weak process discipline.
- Recipe and bill-of-material management with versioning and an approval workflow.
- Batch tracking from active substance to finished good with bidirectional traceability.
- Electronic signatures per FDA 21 CFR Part 11 or EU Annex 11 chapter 7.
- Field-level audit trail, tamper-evident and searchable.
- Multi-stage quality release with role separation between production and QA.
Active-ingredient versus finished-dose: what you must distinguish
Active-ingredient producers and finished-dose manufacturers have structurally different ERP needs: API producers work batch- and campaign-oriented; finished-dose manufacturers work lot-based. An ERP that only supports one creates audit-visible workarounds in the other.
Read next: ERP system fundamentals.
Next step
To assess whether your ERP candidate structurally supports EMA requirements, book a pharma-selection scoping call.
